EMA: Chmp Recommended Granting Marketing Authorisation for Steqeyma to Treat Moderately-to Severely-Active Crohn’s Disease, Plaque Psoriasis
EMA: Chmp建議授予Steqeyma治療中度至嚴重活動性克隆氏症、銀屑病的上市許可。
EMA: Chmp Recommended Granting Marketing Authorisation for Steqeyma to Treat Moderately-to Severely-Active Crohn’s Disease, Plaque Psoriasis
EMA: Chmp建議授予Steqeyma治療中度至嚴重活動性克隆氏症、銀屑病的上市許可。
譯文內容由第三人軟體翻譯。